Novo Nordisk's next-gen obesity drug CagriSema trial results disappoint investors US$ 24.50 Min. order: 1 piece ★★★★★ 4.0 (242 reviews) Sold : Login>>
Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues US$ 23.01 Min. order: 1 piece ★★★★★ 4.7 (84 reviews) Sold : Login>>
Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial? US$ 25.41 Min. order: 1 piece ★★★★★ 4.5 (227 reviews) Sold : Login>>
BPC-157 Peptide 10mg–20mg | Research Grade US$ 20.41 Min. order: 1 piece ★★★★★ 4.7 (24 reviews) Sold : Login>>
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data US$ 25.70 Min. order: 1 piece ★★★★★ 4.0 (89 reviews) Sold : Login>>